BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Popovic M, Matovina-Brko G, Jovic M, Popovic LS. Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. World J Clin Oncol 2022; 13(1): 28-38 [PMID: 35116230 DOI: 10.5306/wjco.v13.i1.28]
URL: https://www.wjgnet.com/2218-4333/full/v13/i1/28.htm
Number Citing Articles
1
Jeannette C. Oosterwijk-Wakka, Mirjam C.A. de Weijert, Gerben M. Franssen, Dimitar R. Kolev, Ton A.F.J. de Haan, Otto C. Boerman, Peter F.A. Mulders, Egbert Oosterwijk. Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancerNeoplasia 2022; 32: 100826 doi: 10.1016/j.neo.2022.100826
2
Wengang Jian, Wei Xue, Tengda Wang, Yongchun Yu, Licheng Cai, Yuyang Meng, Zhinan Xia, Cheng Zhang. RBM4 inhibits the growth of clear cell renal cell carcinoma by enhancing the stability of p53 mRNAMolecular Carcinogenesis 2022;  doi: 10.1002/mc.23499
3
Mosunmoluwa Oyenuga, Mohamed M. G. Mohamed, Sara Sartaj, Rushin Patel, Abayomi Oyenuga, Sandeep Sen. Efficacy and safety of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers: a meta-analysis of randomized controlled trialsImmunopharmacology and Immunotoxicology 2023; 45(1): 10 doi: 10.1080/08923973.2022.2117629
4
Yongchang Lai, Zhibiao Li, Zechao Lu, Hanxiong Zheng, Chiheng Chen, Can Liu, Yafei Yang, Fucai Tang, Zhaohui He. Roles of DNA damage repair and precise targeted therapy in renal cancer (Review)Oncology Reports 2022; 48(6) doi: 10.3892/or.2022.8428